LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain,…
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price78.17 USD
Fair value97.19
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown78.17+0.0% to today
2026-09-04Read Distribution80.03-2.3% to today ✓
2026-07-02Read Markup79.39-1.5% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
LivaNova PLC holds its Markdown at $78.17. Consolidating, no directional conviction, held for 15 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 15 days
Price at the screen
$78.17
Valuation
23.06 trailing · 16.71 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.87
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
16.64%
Below 33%
Interest-bearing debt is just 16.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.12%
Below 33%
Cash held in interest-bearing accounts and securities is 0.1% of assets, under the one-third limit.
Pass
Receivables
32.68%
Below 49%
Money owed to the company is 32.7% of assets, under the 49% limit.
Pass
Revenue purity
1.37%
Below 5%
Only 1.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
LivaNova clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 17%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 24.3% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Buy. The average target sits +17% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Medical tech firm passes ethics but misses opportunity
A patient in Milan getting a nerve stimulator or a heart valve replaced relies on precise kit that must work first time. LivaNova makes those devices across Europe and the US, yet the numbers show only average returns on capital and thin margins for the sector. With revenue growing 14 percent and a forward multiple of 17.4 times, the business clears the ethical screen but does not clear the bar for a real edge over peers.
The 15 percent margin of safety to our fair value sits above the analyst median target of 84 dollars, yet return on equity at 10 percent and an unknown moat leave little room for error if growth slows. Unknown competitive protection plus modest profitability mean the shares are fairly valued at best, not mispriced.
Currency moves across its European markets and any slip in procedure volumes would hit earnings quickly. The rating stays at none because the setup offers safety without upside conviction. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LIVN trades on Nasdaq (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$78.17-2.3%Entry 6
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it buy, with a mean price target of $80.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it buy, with a mean price target of $80.
2026-08-04Markup$80.14+0.9%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it buy, with a mean price target of $80.
2026-07-18Markup$79.39+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it buy, with a mean price target of $80.
2026-07-03Markup$79.39+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$79.39Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
